Salud financiera de hoja de balance de PW Medtech Group

Salud financiera controles de criterios 6/6

PW Medtech Group tiene un patrimonio de accionistas total de CN¥4.8B y una deuda total de CN¥0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son CN¥5.2B y CN¥327.1M respectivamente. El BAIT de PW Medtech Group es de CN¥191.8M, por lo que su ratio de cobertura de intereses es de -4.4. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥1.6B.

Información clave

Ratio deuda-patrimonio

CN¥0

Deuda

Ratio de cobertura de intereses	-4.4x
Efectivo	CN¥1.59b
Patrimonio	CN¥4.82b
Total pasivo	CN¥327.06m
Activos totales	CN¥5.15b

Actualizaciones recientes sobre salud financiera

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

Nov 23

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Dec 28

Recent updates

There's Reason For Concern Over PW Medtech Group Limited's (HKG:1358) Price

Mar 14

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

Nov 23

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

Feb 18

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Nov 22

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥2.0B) de 1358 superan a sus pasivos a corto plazo (CN¥149.3M).

Pasivo a largo plazo: Los activos a corto plazo de 1358 (CN¥2.0B) superan a sus pasivos a largo plazo (CN¥177.8M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 1358 está libre de deudas.

Reducción de la deuda: 1358 no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 12.6%.

Cobertura de la deuda: 1358 no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.

Cobertura de intereses: 1358 no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.

Salud financiera de hoja de balance de PW Medtech Group

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Recent updates

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: EPS: CN¥0.098 (vs CN¥0.068 in FY 2022)

PW Medtech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

There's Reason For Concern Over PW Medtech Group Limited's (HKG:1358) Price

Upcoming dividend of HK$0.049 per share at 11% yield

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

PW Medtech Group Limited to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Market cap size

Full year 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.47 in FY 2021)

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

First half 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.48 in 1H 2021)

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

PW Medtech Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited (SEHK:1358) agreed to acquire 51.5% stake in Beijing Ruijian High-Tech Biological Technology Co., Ltd from a group of shareholders for CNY 412 million.

First half 2021 earnings released: EPS CN¥0.48 (vs CN¥0.09 in 1H 2020)

Investor sentiment improved over the past week

Independent Non-Executive Director Xingdong Zhang has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

PW Medtech Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

New 90-day low: HK$0.52

Should You Rely On PW Medtech Group's (HKG:1358) Earnings Growth?

New 90-day high: HK$2.31

CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358).

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Should You Be Adding PW Medtech Group (HKG:1358) To Your Watchlist Today?

New 90-day high: HK$2.29

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Market bids up stock over the past week

CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358) for approximately $110 million.

New 90-day high: HK$1.76

First half earnings released

PW Medtech Group Limited to Report First Half, 2020 Results on Aug 27, 2020

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera